Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics (VERA)
NASDAQ:VERA
VERA Stock Chart & Stats
$47.69
-$0.18(-0.43%)
At close: 4:00 PM EST
$47.69
-$0.18(-0.43%)
Day’s Range― - ―
52-Week Range$18.53 - $56.05
Previous CloseN/A
Volume142.65K
Average Volume (3M)1.47M
Market Cap
$3.41B
Enterprise Value$1.02B
Total Cash (Recent Filing)$497.39M
Total Debt (Recent Filing)$77.22M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Mar 19, 2026EPS Estimate
-1.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding70,066,180
10 Day Avg. Volume1,120,971
30 Day Avg. Volume1,474,393
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)4.05
Price to Sales (P/S)0.00
P/FCF Ratio-17.25
Enterprise Value/Market Cap0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-908.25
Enterprise Value/Ebitda-4.21
Forecast
1Y Price Target
$74.08Price Target Upside55.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationStrong Phase III results showing substantial proteinuria reduction across prespecified subgroups, together with no neutralizing anti‑drug antibodies reported for atacicept, bolster the drug's competitive differentiation and adoption prospects.
Commercial Opportunity And PricingA favorable precedent from a recently approved IgAN therapy that combined high pricing and no proteinuria cutoff supports expectations of a larger addressable patient population and premium pricing potential for atacicept.
Regulatory ProgressFDA acceptance of atacicept's biologics license application with Priority Review supports the prospect of regulatory approval and a commercial launch into IgA nephropathy.
Bears Say
Class Immunogenicity ConcernsMarked immunogenicity observed with a comparator therapy, where a substantial share of patients developed anti‑drug antibodies with some neutralizing activity, raises concerns about class safety, potential efficacy impacts, and adoption hurdles.
Financing RiskHigh cash burn and a limited cash runway create funding risk and increase dependence on capital markets to support late‑stage development and commercial preparation.
Market Sentiment / Short InterestElevated short interest representing a significant portion of the float signals investor skepticism that could translate into downside pressure or heightened stock volatility.
Vera Therapeutics News
VERA FAQ
What was Vera Therapeutics’s price range in the past 12 months?
Vera Therapeutics lowest stock price was $18.53 and its highest was $56.05 in the past 12 months.
What is Vera Therapeutics’s market cap?
Vera Therapeutics’s market cap is $3.41B.
When is Vera Therapeutics’s upcoming earnings report date?
Vera Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 68 days.
How were Vera Therapeutics’s earnings last quarter?
Vera Therapeutics released its earnings results on Nov 05, 2025. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.162 by -$0.098.
Is Vera Therapeutics overvalued?
According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued.
Does Vera Therapeutics pay dividends?
Vera Therapeutics does not currently pay dividends.
What is Vera Therapeutics’s EPS estimate?
Vera Therapeutics’s EPS estimate is -1.28.
How many shares outstanding does Vera Therapeutics have?
Vera Therapeutics has 70,066,180 shares outstanding.
What happened to Vera Therapeutics’s price movement after its last earnings report?
Vera Therapeutics reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.162. Following the earnings report the stock price went down -1.027%.
Which hedge fund is a major shareholder of Vera Therapeutics?
Currently, no hedge funds are holding shares in VERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.08 (55.34% Upside)
$74.08 (55.34% Upside)
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $293.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.70%
12-Months-Change
Fundamentals
Return on Equity
-73.25%
Trailing 12-Months
Asset Growth
45.62%
Trailing 12-Months
Company Description
Vera Therapeutics
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
VERA Stock 12 Month Forecast
Average Price Target
$74.08
▲(55.34% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
11.34% Insiders
15.73% Mutual Funds
49.40% Other Institutional Investors
11.23% Public Companies and Individual Investors